Sign in
AURA Stock Price, Chart, Stats & News
Aura Biosciences, Inc.
Save
451.97M
Market cap
–
Current P/E
–
Forward P/E
AURA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.11% |
ROA | -56.03% |
ROE | -69.67% |
D/E | 0.11x |
Interest coverage ratio | – |
AURA valuation
P/E | – |
P/S | – |
P/B | 2.64x |
P/CF | -4.69x |
P/FCF | -4.48x |
P/OCF | -4.69x |
PEG | -3.81x |
EV multiple | -4.01x |
About
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma.
Similar securities
Based on sector and market capitalization
Report issue